Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009 Dec 30;655:145–158. doi: 10.1007/978-1-4419-1132-2_11

Virus-Like Particles as a Vaccine Delivery System: Myths and Facts

Polly Roy ‡,✉, Rob Noad ‡
Editors: Carlos A Guzmán6, Giora Z Feuerstein7
PMCID: PMC7124136  PMID: 20047040

Abstract

Vaccines against viral disease have traditionally relied on attenuated virus strains or inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in heterologous systems have been effective for some pathogens, but have often suffered from poor immunogenicity due to incorrect protein folding or modification. In this chapter we focus on a specific class of viral subunit vaccine that mimics the overall structure of virus particles and thus preserves the native antigenic conformation of the immunogenic proteins. These virus-like particles (VLPs) have been produced for a wide range of taxonomically and structurally distinct viruses, and have unique advantages in terms of safety and immunogenicity over previous approaches. With new VLP vaccines for papillomavirus beginning to reach the market place we argue that this technology has now ‘come-of-age’ and must be considered a viable vaccine strategy.

Keywords: Insect Cell, Newcastle Disease Virus, Bovine Leukemia Virus, Subunit Vaccine, Infectious Bursal Disease Virus

References

  • 1.Miyanohara A., Imamura T., Araki M., et al. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol. 1986;59(1):176–80. doi: 10.1128/jvi.59.1.176-180.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Delchambre M., Gheysen D., Thines D., et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 1989;8(9):2653–60. doi: 10.1002/j.1460-2075.1989.tb08405.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gheysen D., Jacobs E., de Foresta F., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 1989;59(1):103–12. doi: 10.1016/0092-8674(89)90873-8. [DOI] [PubMed] [Google Scholar]
  • 4.French T.J., Marshall J.J., Roy P. Assembly of double-shelled, virus-like particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol. 1990;64(12):5695–700. doi: 10.1128/jvi.64.12.5695-5700.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Schirmbeck R., Bohm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology. 1996;39(1–2):111–9. doi: 10.1159/000150482. [DOI] [PubMed] [Google Scholar]
  • 6.Paliard X., Liu Y., Wagner R., et al. Priming of strong, broad and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses. 2000;16(3):273–82. doi: 10.1089/088922200309368. [DOI] [PubMed] [Google Scholar]
  • 7.Murata K., Lechmann M., Qiao M., et al. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA. 2003;100(11):6753–8. doi: 10.1073/pnas.1131929100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11(9):438–44. doi: 10.1016/S0966-842X(03)00208-7. [DOI] [PubMed] [Google Scholar]
  • 9.Maranga L., Rueda P., Antonis A.F., et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol. 2002;59(1):45–50. doi: 10.1007/s00253-002-0976-x. [DOI] [PubMed] [Google Scholar]
  • 10.Zhou J., Sun X.Y., Stenzel D.J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185(1):251–7. doi: 10.1016/0042-6822(91)90772-4. [DOI] [PubMed] [Google Scholar]
  • 11.Kirnbauer R., Booy F., Cheng N., et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992;89(24):12180–4. doi: 10.1073/pnas.89.24.12180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sasagawa T., Pushko P., Steers G., et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology. 1995;206(1):126–35. doi: 10.1016/S0042-6822(95)80027-1. [DOI] [PubMed] [Google Scholar]
  • 13.Dupuy C., Buzoni-Gatel D., Touze A., et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol. 1999;73(11):9063–71. doi: 10.1128/jvi.73.11.9063-9071.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhang L.F., Zhou J., Chen S., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine. 2000;18(11–12):1051–8. doi: 10.1016/S0264-410X(99)00351-5. [DOI] [PubMed] [Google Scholar]
  • 15.Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51. doi: 10.1056/NEJMoa020586. [DOI] [PubMed] [Google Scholar]
  • 16.Evans T.G., Bonnez W., Rose R.C., et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183(10):1485–93. doi: 10.1086/320190. [DOI] [PubMed] [Google Scholar]
  • 17.Harro C.D., Pang Y.Y., Roden R.B., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284–92. doi: 10.1093/jnci/93.4.284. [DOI] [PubMed] [Google Scholar]
  • 18.Franco E.L., Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23(17–18):2388–94. doi: 10.1016/j.vaccine.2005.01.016. [DOI] [PubMed] [Google Scholar]
  • 19.Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–65. doi: 10.1016/S0140-6736(04)17398-4. [DOI] [PubMed] [Google Scholar]
  • 20.Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. doi: 10.1016/S0140-6736(06)68439-0. [DOI] [PubMed] [Google Scholar]
  • 21.Lopez de Turiso J.A., Cortes E., Martinez C., et al. Recombinant vaccine for canine parvovirus in dogs. J Virol. 1992;66(5):2748–53. doi: 10.1128/jvi.66.5.2748-2753.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Martinez C., Dalsgaard K., Lopez de Turiso J.A., et al. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine. 1992;10(10):684–90. doi: 10.1016/0264-410X(92)90090-7. [DOI] [PubMed] [Google Scholar]
  • 23.Antonis A.F., Bruschke C.J., Rueda P., et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine. 2006;24(26):5481–90. doi: 10.1016/j.vaccine.2006.03.089. [DOI] [PubMed] [Google Scholar]
  • 24.Ball J.M., Hardy M.E., Atmar R.L., et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol. 1998;72(2):1345–53. doi: 10.1128/jvi.72.2.1345-1353.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Guerrero R.A., Ball J.M., Krater S.S., et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 2001;75(20):9713–22. doi: 10.1128/JVI.75.20.9713-9722.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ball J.M., Graham D.Y., Opekun A.R., et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology. 1999;117(1):40–8. doi: 10.1016/S0016-5085(99)70548-2. [DOI] [PubMed] [Google Scholar]
  • 27.Tacket C.O., Sztein M.B., Losonsky G.A., et al. Humoral, mucosal and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003;108(3):241–7. doi: 10.1016/S1521-6616(03)00120-7. [DOI] [PubMed] [Google Scholar]
  • 28.Li T.C., Yamakawa Y., Suzuki K., et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol. 1997;71(10):7207–13. doi: 10.1128/jvi.71.10.7207-7213.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Li T., Takeda N., Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine. 2001;19(25–26):3476–84. doi: 10.1016/S0264-410X(01)00059-7. [DOI] [PubMed] [Google Scholar]
  • 30.Li T.C., Suzaki Y., Ami Y., et al. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis e virus-like particles. Vaccine. 2004;22(3–4):370–7. doi: 10.1016/j.vaccine.2003.08.004. [DOI] [PubMed] [Google Scholar]
  • 31.Goldmann C., Petry H., Frye S., et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol. 1999;73(5):4465–9. doi: 10.1128/jvi.73.5.4465-4469.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Caparros-Wanderley W., Clark B., Griffin B.E. Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. Vaccine. 2004;22(3–4):352–61. doi: 10.1016/j.vaccine.2003.08.009. [DOI] [PubMed] [Google Scholar]
  • 33.Brautigam S., Snezhkov E., Bishop D.H. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology. 1993;192(2):512–24. doi: 10.1006/viro.1993.1067. [DOI] [PubMed] [Google Scholar]
  • 34.Kibenge F.S., Qian B., Nagy E., et al. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can J Vet Res. 1999;63(1):49–55. [PMC free article] [PubMed] [Google Scholar]
  • 35.French T.J., Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol. 1990;64(4):1530–6. doi: 10.1128/jvi.64.4.1530-1536.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Belyaev A.S., Hails R.S., Roy P. High-level expression of five foreign genes by a single recombinant baculovirus. Gene. 1995;156(2):229–33. doi: 10.1016/0378-1119(95)00050-G. [DOI] [PubMed] [Google Scholar]
  • 37.Belyaev A.S., Roy P. Development of baculovirus triple and quadruple expression vectors: coexpression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Research. 1993;21(5):1219–23. doi: 10.1093/nar/21.5.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Roy P. Orbiviruses. In: Knipe D.M., Howley P.M., editors. Fields’ Virology. Fourth Edition. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 1835–1869. [Google Scholar]
  • 39.Roy P., French T., Erasmus B.J. Protective efficacy of virus-like particles for bluetongue disease. Vaccine. 1992;10(1):28–32. doi: 10.1016/0264-410X(92)90415-G. [DOI] [PubMed] [Google Scholar]
  • 40.Roy P., Bishop D.H., LeBlois H., et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine. 1994;12(9):805–11. doi: 10.1016/0264-410X(94)90289-5. [DOI] [PubMed] [Google Scholar]
  • 41.Roy P., Urakawa T., Van Dijk A.A., et al. Recombinant virus vaccine for bluetongue disease in sheep. J Virol. 1990;64(5):1998–2003. doi: 10.1128/jvi.64.5.1998-2003.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Sabara M., Parker M., Aha P., et al. Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins. J Virol. 1991;65(12):6994–7. doi: 10.1128/jvi.65.12.6994-6997.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Jiang B., Estes M.K., Barone C., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine. 1999;17(7–8):1005–13. doi: 10.1016/S0264-410X(98)00317-X. [DOI] [PubMed] [Google Scholar]
  • 44.Madore H.P., Estes M.K., Zarley C.D., et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine. 1999;17(19):2461–71. doi: 10.1016/S0264-410X(98)00319-3. [DOI] [PubMed] [Google Scholar]
  • 45.Kim Y., Nielsen P.R., Hodgins D., et al. Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. Vaccine. 2002;20(7–8):1248–58. doi: 10.1016/S0264-410X(01)00404-2. [DOI] [PubMed] [Google Scholar]
  • 46.Nguyen T.V., Yuan L., MS P.A., et al. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine. 2006;24(13):2302–16. doi: 10.1016/j.vaccine.2005.11.043. [DOI] [PubMed] [Google Scholar]
  • 47.Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., et al. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine. 2003;21(25–26):3885–900. doi: 10.1016/S0264-410X(03)00308-6. [DOI] [PubMed] [Google Scholar]
  • 48.Parez N., Fourgeux C., Mohamed A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol. 2006;80(4):1752–61. doi: 10.1128/JVI.80.4.1752-1761.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Agnello D., Herve C.A., Lavaux A., et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an anti-rotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol. 2006;80(8):3823–32. doi: 10.1128/JVI.80.8.3823-3832.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yamshchikov G.V., Ritter G.D., Vey M., et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 1995;214(1):50–8. doi: 10.1006/viro.1995.9955. [DOI] [PubMed] [Google Scholar]
  • 51.Baumert T.F., Ito S., Wong D.T., et al. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol. 1998;72(5):3827–36. doi: 10.1128/jvi.72.5.3827-3836.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. Virol. 2001;75(13):6154–65. doi: 10.1128/JVI.75.13.6154-6165.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Jeong S.H., Qiao M., Nascimbeni M., et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol. 2004;78(13):6995–7003. doi: 10.1128/JVI.78.13.6995-7003.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Mortola E., Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 2004;576(1–2):174–8. doi: 10.1016/j.febslet.2004.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ho Y., Lin P.H., Liu C.Y., et al. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun. 2004;318(4):833–8. doi: 10.1016/j.bbrc.2004.04.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Yao Q., Kuhlmann F.M., Eller R., et al. Production and characterization of simian—human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses. 2000;16(3):227–36. doi: 10.1089/088922200309322. [DOI] [PubMed] [Google Scholar]
  • 57.Wagner R., Deml L., Notka F., et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology. 1996;39(1–2):93–103. doi: 10.1159/000150480. [DOI] [PubMed] [Google Scholar]
  • 58.Yao Q., Vuong V., Li M., et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine. 2002;20(19–20):2537–45. doi: 10.1016/S0264-410X(02)00160-3. [DOI] [PubMed] [Google Scholar]
  • 59.Lechmann M., Murata K., Satoi J., et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 2001;34(2):417–23. doi: 10.1053/jhep.2001.26523. [DOI] [PubMed] [Google Scholar]
  • 60.Galarza J.M., Latham T., Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(1):244–51. doi: 10.1089/vim.2005.18.244. [DOI] [PubMed] [Google Scholar]
  • 61.Pushko P., Tumpey T.M., Bu F., et al. Influenza virus-like particles comprised of the HA, NA and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23(50):5751–9. doi: 10.1016/j.vaccine.2005.07.098. [DOI] [PubMed] [Google Scholar]
  • 62.Garcea R.L., Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol. 2004;15(6):513–7. doi: 10.1016/j.copbio.2004.10.002. [DOI] [PubMed] [Google Scholar]
  • 63.Beyer T., Herrmann M., Reiser C., et al. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr Drug Targets Infect Disord. 2001;1(3):287–302. doi: 10.2174/1568005014605973. [DOI] [PubMed] [Google Scholar]
  • 64.Fausch S.C., Da Silva D.M., Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003;63(13):3478–82. [PubMed] [Google Scholar]
  • 65.Sedlik C., Saron M., Sarraseca J., et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc Natl Acad Sci USA. 1997;94(14):7503–8. doi: 10.1073/pnas.94.14.7503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Fausch S.C., Da Silva D.M., Kast W.M. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005;23(14):1720–9. doi: 10.1016/j.vaccine.2004.09.035. [DOI] [PubMed] [Google Scholar]
  • 67.Lo-Man R., Rueda P., Sedlik C., et al. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol. 1998;28(4):1401–7. doi: 10.1002/(SICI)1521-4141(199804)28:04<1401::AID-IMMU1401>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 68.Charpilienne A., Nejmeddine M. B., Parez N., Neumann E., Hewat E., Trugnan G., Cohen J. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem. 2001;276(31):29361–29367. doi: 10.1074/jbc.M101935200. [DOI] [PubMed] [Google Scholar]
  • 69.Ghosh M.K., Deriaud E., Saron M.F., et al. Induction of protective anti-viral cytotoxic T-cells by a tubular structure capable of carrying large foreign sequences. Vaccine. 2002;20(9–10):1369–77. doi: 10.1016/S0264-410X(01)00467-4. [DOI] [PubMed] [Google Scholar]
  • 70.Ghosh M.K., Borca M.V., Roy P. Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4 + Th cell and protective humoral responses. Virology. 2002;302(2):383–92. doi: 10.1006/viro.2002.1648. [DOI] [PubMed] [Google Scholar]
  • 71.Larke N., Murphy A., Wirblich C., et al. Induction of human immunodeficiency virus type 1-specific T-cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J Virol. 2005;79(23):14822–33. doi: 10.1128/JVI.79.23.14822-14833.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Lindenburg C.E., Stolte I., Langendam M.W., et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine. 2002;20(17–18):2343–7. doi: 10.1016/S0264-410X(02)00102-0. [DOI] [PubMed] [Google Scholar]
  • 73.Kirnbauer R., Taub J., Greenstone H., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol. 1993;67(12):6929–36. doi: 10.1128/jvi.67.12.6929-6936.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Jiang X., Wang M., Graham D.Y., et al. Expression, self-assembly and anti-genicity of the Norwalk virus capsid protein. J Virol. 1992;66(11):6527–32. doi: 10.1128/jvi.66.11.6527-6532.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Laurent S., Vautherot J.F., Madelaine M.F., et al. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol. 1994;68(10):6794–8. doi: 10.1128/jvi.68.10.6794-6798.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Pletneva M.A., Sosnovtsev S.V., Sosnovtseva S.A., et al. Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells. Virus Res. 1998;55(2):129–41. doi: 10.1016/S0168-1702(98)00045-8. [DOI] [PubMed] [Google Scholar]
  • 77.Hale A.D., Crawford S.E., Ciarlet M., et al. Expression and self-assembly of Grimsby virus: anti-genic distinction from Norwalk and Mexico viruses. Clin Diagn Lab Immunol. 1999;6(1):142–5. doi: 10.1128/cdli.6.1.142-145.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Belliot G., Noel J.S., Li J.F., et al. Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of “Norwalk-like viruses”. J Clin Microbiol. 2001;39(12):4288–95. doi: 10.1128/JCM.39.12.4288-4295.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Brown C.S., Van Lent J.W., Vlak J.M., et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol. 1991;65(5):2702–6. doi: 10.1128/jvi.65.5.2702-2706.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Christensen J., Alexandersen S., Bloch B., et al. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J Gen Virol. 1994;75(Pt 1):149–55. doi: 10.1099/0022-1317-75-1-149. [DOI] [PubMed] [Google Scholar]
  • 81.Hoque M., Shimizu N., Ishizu K., et al. Chimeric virus-like particle formation of adeno-associated virus. Biochem Biophys Res Commun. 1999;266(2):371–6. doi: 10.1006/bbrc.1999.1831. [DOI] [PubMed] [Google Scholar]
  • 82.Koch G., van Roozelaar D.J., Verschueren C.A., et al. Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus. Vaccine. 1995;13(8):763–70. doi: 10.1016/0264-410X(94)00034-K. [DOI] [PubMed] [Google Scholar]
  • 83.Noteborn M.H., Verschueren C.A., Koch G., et al. Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J Gen Virol. 1998;79(Pt 12):3073–7. doi: 10.1099/0022-1317-79-12-3073. [DOI] [PubMed] [Google Scholar]
  • 84.Albina E., Truong C., Hutet E., et al. An experimental model for post-weaning multisystemic wasting syndrome (PMWS) in growing piglets. J Comp Pathol. 2001;125(4):292–303. doi: 10.1053/jcpa.2001.0508. [DOI] [PubMed] [Google Scholar]
  • 85.Kim Y., Kim J., Kang K., et al. Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system. J Vet Sci. 2002;3(1):19–23. [PubMed] [Google Scholar]
  • 86.Kosukegawa A., Arisaka F., Takayama M., et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim Biophys Acta. 1996;1290(1):37–45. [PubMed] [Google Scholar]
  • 87.Chang D., Fung C.Y., Ou W.C., et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol. 1997;78(Pt 6):1435–9. doi: 10.1099/0022-1317-78-6-1435. [DOI] [PubMed] [Google Scholar]
  • 88.Brautigam S., Snezhkov E., Bishop D.H. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology. 1993;192(2):512–24. doi: 10.1006/viro.1993.1067. [DOI] [PubMed] [Google Scholar]
  • 89.Crawford S.E., Labbe M., Cohen J., et al. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 1994;68(9):5945–22. doi: 10.1128/jvi.68.9.5945-5952.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Overton H.A., Fujii Y., Price I.R., et al. The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology. 1989;170(1):107–116. doi: 10.1016/0042-6822(89)90357-7. [DOI] [PubMed] [Google Scholar]
  • 91.Rasmussen L., Battles J.K., Ennis W.H., et al. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology. 1990;178(2):435–51. doi: 10.1016/0042-6822(90)90341-N. [DOI] [PubMed] [Google Scholar]
  • 92.Morikawa S., Booth T.F., Bishop D.H. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virology. 1991;183(1):288–97. doi: 10.1016/0042-6822(91)90141-W. [DOI] [PubMed] [Google Scholar]
  • 93.Thomsen D.R., Meyer A.L., Post L.E. Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. J Gen Virol. 1992;73(Pt 7):1819–24. doi: 10.1099/0022-1317-73-7-1819. [DOI] [PubMed] [Google Scholar]
  • 94.Rafnar B., Tobin G.J., Nagashima K., et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res. 1998;53(2):107–20. doi: 10.1016/S0168-1702(97)00141-X. [DOI] [PubMed] [Google Scholar]
  • 95.Kakker N., Mikhailov M., Nermut M.V., et al. Bovine leukemia virus Gag particle assembly in insect cells: Formation of chimeric particles by domain-switched leukemia/lentitivirus Gag polyprotein. Virology. 1999;2(265):303–318. doi: 10.1006/viro.1999.0007. [DOI] [PubMed] [Google Scholar]
  • 96.Johnson M.C., Scobie H.M., Vogt V.M. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J Virol. 2001;75(9):4407–12. doi: 10.1128/JVI.75.9.4407-4412.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Nagy E., Huber P., Krell P.J., et al. Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. J Gen Virol. 1991;72(Pt 3):753–6. doi: 10.1099/0022-1317-72-3-753. [DOI] [PubMed] [Google Scholar]
  • 98.Betenbaugh M., Yu M., Kuehl K., et al. Nucleocapsid-and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res. 1995;38(2–3):111–24. doi: 10.1016/0168-1702(95)00053-S. [DOI] [PubMed] [Google Scholar]
  • 99.Fernandez-Arias A., Risco C., Martinez S., et al. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J Gen Virol. 1998;79(Pt 5):1047–54. doi: 10.1099/0022-1317-79-5-1047. [DOI] [PubMed] [Google Scholar]
  • 100.Martinez-Torrecuadrada J.L., Saubi N., Pages-Mante A., et al. Structure dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. Vaccine. 2003;21(23):3342–50. doi: 10.1016/S0264-410X(02)00804-6. [DOI] [PubMed] [Google Scholar]

Articles from Pharmaceutical Biotechnology are provided here courtesy of Nature Publishing Group

RESOURCES